NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (HM43205)

Hemophilia treatment center, Ohio, calendar year 2025. Everything below is as the workbook stored it, with figures shown to the cent. Each section follows the Ohio Department of Health's template, in its order and words.

The name is HRSA's, from its public list of covered entities read on 11 November 2026. The workbook prints the 340B ID and no name.

About this workbook

340B ID
  • HM43205 NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (Hemophilia treatment center)
Reporting period as typed
January 1, 2025 - December 31, 2025
Form
Ohio Department of Health, ORC 3701.88 340B Covered Entity Reporting Template, calendar year 2025

Drugs dispensed in house

Drugs the covered entity dispensed through its own pharmacies.

Drugs dispensed in house, as stored, for NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (HM43205)
Row of the templateCommercial Insurance/Private InsuranceMedicareMedicaid (all states)Other Third-Party PayorUninsured/Self-PayTotal
Acquisition costAggregate Acquisition Cost for all 340B drugs dispensed by the Covered Entity$6,342,184$0$8,091,289$1,406,717$0$15,840,190
Payments receivedAggregate Payments Received for all 340B drugs dispensed by the Covered Entity$8,312,489$0$11,024,901$2,370,963$0$21,708,353
All prescriptionsTotal number of Prescriptions dispensed by the Covered Entity (340B and non-340B)1910369750635
340B prescriptionsTotal number of Prescriptions dispensed by the Covered Entity (340B)1910369750635
Percentage that were 340BPercentage of total prescriptions that were 340B100%#DIV/0!100%100%#DIV/0!100%

Drugs dispensed through contract pharmacies

Drugs contract pharmacies dispensed on behalf of the covered entity.

Drugs dispensed through contract pharmacies, as stored, for NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (HM43205)
Row of the templateCommercial Insurance/Private InsuranceMedicareMedicaid (all states)Other Third-Party PayorUninsured/Self-PayIndeterminate (Explain)Total
Acquisition costAggregate Acquisition Cost for all 340B drugs dispensed by all Contract Pharmacies on behalf of the Covered Entity above:N/AN/AN/AN/AN/AN/A$0
Payments receivedAggregate Payments Received for all 340B drugs dispensed by all Contract Pharmacies on behalf of the Covered Entity above:N/AN/AN/AN/AN/AN/A$0
All prescriptionsTotal number of Prescriptions filled by all Contract Pharmacies on behalf of the Covered Entity (340B and non-340B):N/AN/AN/AN/AN/AN/A0
340B prescriptionsTotal number of 340B Prescriptions filled by all Contract Pharmacies on behalf of the Covered Entity:N/AN/AN/AN/AN/AN/A0
Percentage that were 340BPercentage of total Covered-Entity associated prescriptions that were 340B:#VALUE!#VALUE!#VALUE!#VALUE!#VALUE!#VALUE!#DIV/0!

Drugs administered

Drugs the covered entity administered, for example by infusion or injection.

Drugs administered, as stored, for NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (HM43205)
Row of the templateCommercial Insurance/Private InsuranceMedicareMedicaid (all states)Other Third-Party PayorUninsured/Self-PayTotal
Acquisition costAggregate Acquisition Cost for all 340B drugs administered by the Covered EntityN/AN/AN/AN/AN/A$0
Actual paymentsAggregate Payments Received for all 340B drugs administered by the Covered Entity - Actual PaymentsN/AN/AN/AN/AN/A$0
Estimated paymentsAggregate Payments Received for all 340B drugs administered by the Covered Entity - Estimated Payments*N/AN/AN/AN/AN/A$0
Total paymentsAggregate Payments Received for all 340B drugs administered by the Covered Entity - TOTALN/AN/AN/AN/AN/A$0
All prescriptionsTotal number of Prescriptions administered by the Covered Entity (340B and non-340B)N/AN/AN/AN/AN/A0
340B prescriptionsTotal number of Prescriptions administered by the Covered Entity (340B)N/AN/AN/AN/AN/A0
Percentage that were 340BPercentage of total prescriptions that were 340B#VALUE!#VALUE!#VALUE!#VALUE!#VALUE!#DIV/0!

Figures are shown to the cent. The downloads keep each figure exactly as it is written in the file, and the cell file lists the workbook cell each one was read from.

Costs of running the program

Amounts in US dollars, as the workbook stores them.

Costs, as stored, for NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (HM43205)
CostAmountCell
Contract pharmacies$3,797,549 (Note: These are payments to in-house pharmacy, given there is no dedicated in-house pharmacy field)C46
Third-party administrators$0C47
Consultants$4,250C48
Software and IT$0C49
Other outside costs$63,253C50
Staffing$1,122,412C53
Internal IT$0C54
Other internal costs$717C55

Contract pharmacies

Number of contract pharmacies as typed
0

Explanation of the Indeterminate column, as typed

N/A

Uses of 340B funds

What the filer typed under the template's questions about how it uses the money 340B brings in. A dash or an empty cell is left out.

Uses of 340B funds, as typed, for NATIONWIDE CHILDREN'S HOSPITAL (HEMOSTASIS & THROMBOSIS CENTER) (HM43205)
KindDescriptionAmountCell
Program or serviceSee #24See #24C65
Program or serviceSee #24See #24C66
Program or serviceSee #24See #24C67
Program or serviceSee #24See #24C68
Program or serviceSee #24See #24C69
ItemN/A$0C72
ItemN/A$0C73
ItemN/A$0C74
ItemN/A$0C75
ItemN/A$0C76
Other useN/A$0C78

Narrative, as typed

N/A

Narrative given where the entity cannot detail its uses, as typed

Note on #2 above - the NPIs of our hematology providers are included above. NPIs of our oncology and BMT physicans can also be provided on request (limited space in collection tool). Introduction: The 340B Drug Pricing Program intends to enable covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. For Nationwide Children's, this program is critical to supporting our mission of providing the highest quality of care to all children and their families, regardless of their ability to pay. The 340B savings achieved through our Hemostasis and Thrombosis Center are reinvested directly into care and advocacy for our patient population. Comprehensive Care Model: Through 340B savings, the Hemostasis and Thrombosis Center at Nationwide Children’s Hospital is able to offer a comprehensive care model that serves as a one-stop-shop for patients and families with bleeding and clotting disorders. This model includes a multidisciplinary team of physicians, nurse practitioners, nurse clinicians, nurses, genetic counselors, psychologists, pharmacists, dental hygienists, psychologists, among others. These disciplines work collaboratively to ensure the best possible outcomes and experience for patients and their families. Additionally, Nationwide Children’s is home to one of the oldest Young Women’s Hematology clinics in the country, combining expertise in hemostasis-thrombosis and adolescent medicine. This specialized clinic provides a compassionate, patient-centered approach for adolescent girls with suspected bleeding and clotting disorders and offers advanced diagnostic and treatment options for those experiencing heavy menstrual bleeding. Professional Education and Training: The education and development of hemostasis and thrombosis experts is also a top priority. Nationwide Children’s Hospital offers a fourth-year fellowship for physicians seeking to expand their expertise in hemostasis and thrombosis, helping to address a growing workforce shortage of adequately trained physicians in this field. Fellows complete a comprehensive curriculum including, outpatient clinical care, inpatient service, research, quality improvement, teaching opportunities, and select elective rotations. Research: Research is a central focus of the Hemostasis and Thrombosis Center at Nationwide Children’s. HTC funds are currently being reserved for a research study evaluating a new treatment for rare congenital bleeding disorders. The study aims to assess the effectiveness of a drug in mice that blocks a protein responsible for slowing down blood clotting. By blocking this protein, the body can produce more thrombin, a key enzyme that helps blood clot. If successful in mice, this research could lead to a new treatment option for individuals with rare congenital bleeding disorders, potentially reducing the need for therapies that require blood transfusions. This project is currently under review by HRSA. Laboratory Medicine: The Hemostasis and Thrombosis Center at Nationwide Children’s Hospital has invested in a Director of Hemostasis and Thrombosis Testing within the Division of Pathology and Laboratory Medicine. This position is responsible for reviewing and interpreting lab tests related to bleeding and clotting conditions, diagnosing new cases of hemophilia, identifying other congenital or acquired coagulopathies, detecting and quantifying acquired inhibitors, and advising on approaches to multiple factor concentrate monitoring. The role also includes interpretation of platelet function testing and the detection and diagnosis of both acquired and congenital thrombophilia. Additionally, the Director collaborates closely with hematology physician partners to assess the feasibility of introducing new laboratory tests. This role also has an important teaching component, providing education to residents and fellows on laboratory administration, how lab tests for bleeding and clotting work, how medications that affect clotting are monitored, and how lab results guide decisions about blood transfusions and patient treatment. Community Outreach and Education: The Hemostasis and Thrombosis Center at Nationwide Children’s is a recipient of a grant from the CASCADE Hemophilia Consortium, enabling the Center to provide additional support to patients and families in need. This includes assistance with medical expenses, transportation, among other items. Nationwide Children’s also hosts a Family Education Day at the Columbus Zoo for patients with bleeding disorders and their families. This event covers a wide range of topics, including infusion education, mental health, genetics, and transitioning from pediatric to adult healthcare providers. Additional sessions address school-related concerns, finding additional community resources, available hemophilia camps for children and young adults, and navigating health insurance. School outreach is another key priority. The Hemophilia and Thrombosis Center team provides education to daycare, preschool, and school staff on hemophilia and strategies to support students with bleeding disorders in educational settings. Our staff also partner with the Greater Ohio Bleeding Disorders Foundation, providing community education at local events. Finally, Nationwide Children’s supports FAMOHIO, an organization that hosts an Education Weekend for individuals and families affected by bleeding disorders.

The filer in the workbook

340B ID as typed
HM43205
NPIs as typed
  • 1184829301
  • 1194756049
  • 1205125887
  • 1679552392
  • 1760576300
  • 1548247406
  • 1912192535
  • 1780941393
  • 1790179943
  • 1306868740
  • 1477927598
  • 1427799287
  • 1932621653
  • 1336935030
  • 1023214673
  • 1164950697
  • 1396730073
  • 1922553296

Differences in this workbook

No difference was found between this workbook's own figures by the rules in Methods.

Source

Workbook
Open HM43205.xlsx on the Ohio Department of Health's website
Size
26 KB
Retrieved
16 November 2026
SHA-256
349a1d5fd408ab5349d4ac29e5ddf9c141ee0cffd8df49af6846ab931fdaa309
How it was read
Two separate programs read each cell of the workbook, and a value is kept when their reads agree. The cells of this workbook are listed one by one in the dataset repository.